News | May 13, 2023
Cipla reports Q4 FY 23 consolidated PAT at Rs. 525.65 Cr
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
This decision will accelerate growth for both its pharma & consumer healthcare businesses in India
The company has reported total income of Rs. 187.75 crores during the period ended March 31, 2023
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
Sunrise is built on four elements i.e., Awareness, Screening & Diagnosis, Treatment, and Maintenance Support
The company has reported total income of Rs. 211.62 crores during the period ended March 31, 2023
Wider reach for nutraceuticals portfolio in Europe, Turkey and Egypt
The company has reported total income of Rs. 4467.35 crores during the quarter ended March 31, 2023
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
Subscribe To Our Newsletter & Stay Updated
